Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29114066 | 0.85 | LMNA (0.52) | LMNAALDH1A1TDP1OR51E2 | |
| Succinic Acid SCHEMBL8366457 | 0.83 | LMNA (0.53) | EGLN1LMNAALKBH5SUCNR1ALDH1A1 | |
| SCHEMBL5744776 | 0.83 | KMT2A (0.56) | LMNAALDH1A1TDP1OR51E2 | |
| SCHEMBL12970907 | 0.83 | KMT2A (0.56) | LMNAALDH1A1TDP1OR51E2 | |
| SCHEMBL11519181 | 0.83 | KMT2A (0.56) | LMNAALDH1A1TDP1OR51E2 | |
| SCHEMBL8509023 | 0.82 | EGLN1 (0.46) | EGLN1KDM4EKDM6BKDM5CPHF8 | |
| SCHEMBL10589449 | 0.80 | CYP1A2 (0.56) | EGLN1KDM4EKDM6BKDM5CPHF8 | |
| SCHEMBL30122637 | 0.80 | GABRP (0.50) | KDM2AALDH1A1TDP1GABRPGABRD | |
| Hydrogen Peroxide SCHEMBL16799548 | 0.80 | CYP2C19 (0.56) | ALDH1A1TDP1CYP2C19CA2CACNA2D1 | |
| SCHEMBL12232369 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951038-B2 | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170143835-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2017-05-25 | — | — | US | disclosed |
| US-20170143835-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ADOCIA (FR) | 2017-05-25 | — | — | US | disclosed |
| US-9453051-B2 | Cyclosporin derivatives | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-09-27 | — | — | US | disclosed |
| US-20160002203-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | TADESSE DAWIT (US) | 2016-01-07 | — | — | US | disclosed |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | LEAD DISCOVER CENTER GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-2598504-A1 | PROCESS FOR THE PREPARATION OF DIMIRACETAM | Neurotune AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013640-A1 | PROCESS FOR THE PREPARATION OF DIMIRACETAM | NEUROTUNE AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| US-20110136722-A1 | Drug Delivery Carrier | Pronexx Co., Ltd. (KR) | 2011-06-09 | — | — | US | disclosed |
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| CN-101639438-A | Detection method of lead content in gasoline | PETROCHINA CHANGQING PETROCHEM | 2010-02-03 | — | — | CN | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-5130319-A | Cognition activators for memory disorders | I.S.F. SOCIETA PER AZIONI (IT) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136722-A1 | Drug Delivery Carrier | SLC7A1, VEGFA, SLC7A5 | EGLN1 4014/4885KDM4E 3526/4885KDM6B 1758/4885 |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | EGLN1 1401/4885KDM4E 1091/4885KDM6B 1696/4885 |
| US-20170143835-A1 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS | ALG8, FUT8, UGT8 | EGLN1 3468/4885KDM4E 3777/4885KDM6B 3604/4885 |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | CHP1, RYR2, CANX | EGLN1 4566/4885KDM4E 3080/4885KDM6B 4245/4885 |
| US-20160002203-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | OPRK1, OPRD1, P2RX4 | EGLN1 509/4885KDM4E 1369/4885KDM6B 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.